

RWANDA Support for Rotavirus Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Rwanda			
2. Grant number: 18-RWA-13b-X / 18-RWA-13b-A / 12-RWA-08a-Y			
3. Date of Decision Letter: 28 February 2018			
4. Date of the Partnership Framework Agreement: 7 June 2013			
5. Programme title: New Vaccine Support (NVS), Rotavirus Routine			
6. Vaccine type: Rotavirus			
7. Requested product presentation and formulation of vaccine: Rotavirus, 2 dose(s) schedule			
8. Programme duration¹: 2012 -2018			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)			
	2012-2017	2018	Total²
Programme Budget (US\$)	24,445,111 ³	1,357,500	25,802,611
Refugee doses (Gavi supported):			
		2018	
	Programme Budget (US\$)	17,000	
10. Vaccine introduction grant (in US\$): \$126,500 was disbursed on 30/01/2012			

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

11. Gavi Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable)⁴

Type of supplies to be purchased with Gavi funds in each year	2012-2017	2018
Number of Rotavirus vaccines doses		652,500
Annual Amounts (US\$)	24,445,111 ⁵	1,357,500

Refugee doses (Gavi supported):

Type of supplies to be purchased with Gavi funds in each year	2018
Number of Rotavirus vaccines doses	7,500
Annual Amount (US\$)	17,000

12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

13. Self-procurement: Not Applicable

14. Co-financing obligations: Reference code: 18-RWA-13b-X-C
According to the co-financing policy, the Country falls within the group Initial self-financing.
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2018
Number of vaccine doses	70,500
Value of vaccine doses (US\$)	140,016
Total co-financing payments (US\$) (including freight)	145,000

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

Refugee doses (amount to be paid by UNICEF): Reference code: 18-RWA-13b-A-C

Type of supplies to be purchased with Country funds in each year	2018
Number of vaccine doses	1,500
Value of vaccine doses (US\$)	1,743
Total co-financing payments (US\$) (including freight)	2,000

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements:

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable

18. Other conditions: Not applicable

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes
28 February 2018

RWANDA Support for Pentavalent Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Rwanda			
2. Grant number: 18-RWA-04c-X /18-RWA-04c-A			
3. Date of Decision Letter: 28 February 2018			
4. Date of the Partnership Framework Agreement: 7 June 2013			
5. Programme title: New Vaccine Support (NVS), Pentavalent Routine			
6. Vaccine type: Pentavalent			
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 10 dose(s) per vial, LIQUID			
8. Programme duration¹: 2002-2018			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)			
	2002-2017	2018	Total²
Programme Budget (US\$)	46,269,348 ³	596,500	46,865,848
Refugee doses (Gavi supported):			
		2018	
	Programme Budget (US\$)	8,000	
10. Vaccine introduction grant (in US\$): . Not applicable			

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

11. Gavi Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable)⁴

Type of supplies to be purchased with Gavi funds in each year	2002-2017	2018
Number of Pentavalent vaccines doses		767,500
Annual Amounts (US\$)	46,269,348 ₅	596,500

Refugee doses (Gavi supported):

Type of supplies to be purchased with Gavi funds in each year	2018
Number of Pentavalent vaccines doses	10,000
Annual Amounts (US\$)	8,000

12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

13. Self-procurement: Not applicable

14. Co-financing obligations: Reference code: 18-RWA-04c-X-C
According to the co-financing policy, the Country falls within the group Initial self-financing.
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2018
Number of vaccine doses	266,500
Value of vaccine doses (US\$)	199,652
Total co-financing payments (US\$) (including freight)	207,000

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

Refugee doses (amount to be paid by UNICEF): Reference code: 18-RWA-04c-A-C

Type of supplies to be purchased with Country funds in each year	2018
Number of vaccine doses	3,500
Value of vaccine doses (US\$)	2,607
Total co-financing payments (US\$) (including freight)	3,000

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements:

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable

18. Other conditions: Not applicable

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes
28 February 2018

RWANDA Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Rwanda			
2. Grant number: 18-RWA-12d-X / 18-RWA-12d-A / 08-RWA-08b-Y / 09-RWA-08c-Y / 17-RWA-25a-Y			
3. Date of Decision Letter: 28 February 2018			
4. Date of the Partnership Framework Agreement: 7 June 2013			
5. Programme title: New Vaccine Support (NVS), Pneumococcal Routine			
6. Vaccine type: Pneumococcal			
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 4 doses per vial, Liquid			
8. Programme duration¹: 2009 -2018			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)			
	2009-2017	2018	Total²
Programme Budget (US\$)	32,190,692 ³	3,508,500	35,699,192
Refugee doses (Gavi supported):			
		2018	
	Programme Budget (US\$)	40,000	
10. Vaccine introduction grant (in US\$) / Product switch grant (in US\$): . A VIG of US\$117,000 was disbursed on 06/08/2008, a VIG of US\$422,650 was disbursed on 20/02/2009 and a PSG of US\$87,707 was disbursed on 31/08/2017.			

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

11. Gavi Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable)⁴

Type of supplies to be purchased with Gavi funds in each year	2009-2017	2018
Number of Pneumococcal vaccines doses		1,044,800
Annual Amounts (US\$)	32,190,692 ⁵	3,508,500

Refugee doses (Gavi supported):

Type of supplies to be purchased with Gavi funds in each year	2018
Number of Pneumococcal vaccines doses	11,600
Annual Amounts (US\$)	40,000

12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

13. Self-procurement: Not applicable

14. Co-financing obligations: Reference code: 18-RWA-12d-X-C
According to the co-financing policy, the Country falls within the group Initial self-financing.
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2018
Number of vaccine doses	73,000
Value of vaccine doses (US\$)	222,219
Total co-financing payments (US\$) (including freight)	224,000

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

Refugee doses (amount to be paid by UNICEF): Reference code: 18-RWA-12d-A-C

Type of supplies to be purchased with Country funds in each year	2018
Number of vaccine doses	1,000
Value of vaccine doses (US\$)	2,505
Total co-financing payments (US\$) (including freight)	3,000

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements:

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable

18. Other conditions: Not applicable

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes
28 February 2018

RWANDA
Support for Human Papillomavirus Vaccine (HPV)

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Rwanda			
2. Grant number: 18-RWA-19b-X			
3. Date of Decision Letter: 28 February 2018			
4. Date of the Partnership Framework Agreement: 7 June 2013			
5. Programme title: New Vaccine Support (NVS), HPV Routine			
6. Vaccine type: Human Papillomavirus Vaccine (HPV)			
7. Requested product presentation and formulation of vaccine: HPV Quadrivalent, 1 dose(s) per vial, LIQUID			
8. Programme duration¹: 2014 -2018			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)			
	2014-2017	2018	Total²
Programme Budget (US\$)	6,056,034 ³	1,275,000	7,331,034
10. Vaccine introduction grant (in US\$): Not applicable			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴			
Type of supplies to be purchased with Gavi funds in each year	2014-2017	2018	
Number of HPV vaccines doses		280,600	
Annual Amounts (US\$)	6,056,034 ⁵	1,275,000	

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.									
13. Self-procurement: Not applicable									
<p>14. Co-financing obligations: Reference code: 18-RWA-19b-X-C According to the co-financing policy, the Country falls within the group Initial self-financing. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th>2018</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>13,000</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>58,144</td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>59,000</td> </tr> </tbody> </table>		Type of supplies to be purchased with Country funds in each year	2018	Number of vaccine doses	13,000	Value of vaccine doses (US\$)	58,144	Total co-financing payments (US\$) (including freight)	59,000
Type of supplies to be purchased with Country funds in each year	2018								
Number of vaccine doses	13,000								
Value of vaccine doses (US\$)	58,144								
Total co-financing payments (US\$) (including freight)	59,000								
15. Operational support for campaigns: Not applicable									
16. Additional reporting requirements:									
Reports and other information	Due dates								
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018								
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat								
17. Financial clarifications: Not applicable									
18. Other conditions: Not applicable									

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes
28 February 2018

RWANDA
Support for Inactivated Polio Vaccine (IPV)

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Rwanda			
2. Grant number(s): 1518-RWA-25c-X / 15-RWA-08h-Y			
3. Date of Decision Letter: 28 February 2018			
4. Date of the Partnership Framework Agreement: 7 June 2013			
5. Programme title: NVS, IPV routine			
6. Vaccine type: Inactivated Polio Vaccine (IPV)			
7. Requested product presentation and formulation of vaccine¹: Inactivated Polio Vaccine, 10 dose(s) per vial, LIQUID			
8. Programme duration²: 2015 - 2018			
9. Indicative Programme Budget: (subject to the terms of the Partnership Framework Agreement, if applicable) <i>Please note that endorsed or approved amounts for 2019 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.</i>			
	2015-2017	2018	Total³
Routine Programme (US\$)	36,774 ⁴	306,000	342,774
Catch-up vaccination (US\$)			
Total Budget (US\$)	36,774	306,000	342,774
10. Vaccine introduction grant: A VIG of US\$338,000 was disbursed on 5/3/2015.			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁵			
Number of vaccines to be purchased with Gavi funds	2015-2017	2018	
IPV Routine Programme (doses)		368,700	
IPV Catch-up vaccination (doses)			
Annual Amounts (doses)	36,774	368,700	

¹ Please refer to section 18 for additional information on IPV presentation.

² This is the entire duration of the Programme.

³ This is the total amount endorsed by Gavi for 2015 to 2018.

⁴ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁵ This is the amount that Gavi has approved.

12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.							
13. Self-procurement: Not applicable							
14. Co-financing obligations: Not applicable Gavi's usual co-financing requirements do not apply to IPV. However, Rwanda is encouraged to contribute to vaccine and/or supply costs for IPV.							
15. Operational support for catch-up campaigns: Not applicable							
16. Additional reporting requirements:							
<table border="1"> <thead> <tr> <th>Reports and other information</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td> <td>15 May 2018</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> </tbody> </table>		Reports and other information	Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
Reports and other information	Due dates						
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018						
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat						
17. Financial clarifications: Not applicable							
18. Other conditions:							
<p>Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.</p> <p>If Rwanda envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Rwanda.</p>							

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes
28 February 2018

RWANDA Support for Measles-Rubella Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Rwanda			
2. Grant number: 18-RWA-09a-X / 18-RWA-18e-A / 17-RWA-34a-X / 17-RWA-35a-Y			
3. Date of Decision Letter: 28 February 2018			
4. Date of the Partnership Framework Agreement: 7 June 2013			
5. Programme title: New vaccine support (NVS), Measles Second Dose as Measles-Rubella and Measles-Rubella 1st and 2nd dose (Eligibility for refugees), Measles-Rubella Follow-up campaign			
6. Vaccine type: Measles-Rubella			
7. Requested product presentation and formulation of vaccine: Measles Rubella, 10 dose(s) per vial, LYOPHILISED			
8. Programme duration¹: 2015 -2018			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)			
		2017	
Programme Budget (Campaign) (US\$)		983,490 ²	
	2015-2017	2018	Total³
Programme Budget (US\$)	414,442 ⁴	141,500	555,942
Refugee doses (Routine, Gavi supported):			
		2018	Total⁵
Programme Budget (US\$)		4,500	4,500

¹ This is the entire duration of the Programme.

² This is the consolidated amount for all previously approved years.

³ This is the total amount endorsed by Gavi for the entire duration of the Programme.

⁴ This is the consolidated amount for all previous years.

⁵ This is the total amount endorsed by Gavi for the entire duration of the Programme.

10. Gavi Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable)⁶

Type of supplies to be purchased with Gavi funds in each year (Campaign)	2017
Number of Measles-Rubella vaccines doses	1,577,000
Annual Amounts (US\$)	983,490 ⁷

Type of supplies to be purchased with Gavi funds in each year (Routine)	2015-2017	2018
Number of Measles vaccines doses		504,900
Annual Amounts (US\$)	414,442 ⁸	141,500

Refugee doses (Routine, Gavi supported):

Type of supplies to be purchased with Gavi funds in each year (Routine)	2018
Number of Measles-Rubella vaccines doses	6,700
Annual Amounts (US\$)	4,500

11. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

12. Self-procurement: Not applicable

13. Co-financing obligations for routine

Refugee doses (amount to be paid by UNICEF): Reference code: 18-RWA-18e-A-C

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2018
Number of vaccine doses	5,900
Value of vaccine doses (US\$)	3,626

⁶ This is the amount that Gavi has approved.

⁷ This is the consolidated amount for all previously approved years.

⁸ This is the consolidated amount for all previously approved years.

Total co-financing payments (US\$) (including freight)	4,000
Minimum number of doses to be financed from domestic resources	6,300
Minimum amount to be financed from domestic resources (US\$)	3,893
14. Operational support for campaigns: \$923,434 was disbursed on 31/7/2017	
15. Additional reporting requirements:	
Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
16. Financial clarifications: Not applicable	
17. Other conditions:	
Country has presented an official request to Gavi to switch from measles vaccine to measles- rubella vaccine for the routine measles second dose with country funding for the equivalent cost of the rubella component. As such, country will make the required payments to UNICEF SD as indicated in the table below.	
	2018
Number of doses of vaccines for Measles Second Dose approved by Gavi.	504,900
Amount for vaccines approved by Gavi in US\$ (excluding freight and insurance).	136,323
Number of doses of Measles-Rubella vaccine that can be purchased with Gavi support.	220,857
Number of doses of Measles-Rubella vaccine to be funded by country.	284,313
Amount for Measles-Rubella vaccines to be funded by country (excluding freight and insurance).	175,705
In the case of procurement through UNICEF, Gavi-funded vaccines will be purchased only after receipt of full payment of the respective amounts due from Country for the number of doses as indicated in this Decision Letter. Country is required to submit a request for a Cost Estimate to UNICEF, with a clear reference	

to the approval code and approval year. Country will inform Gavi Secretariat when payment of the respective amount due under this Cost Estimate has been fully made to UNICEF.

In the event that country wishes to revert to measles vaccine, country should inform UNICEF and Gavi immediately in order to agree on an appropriate arrangement.

On behalf of Gavi

Hind A. Khatib

Hind Khatib-Othman
Managing Director, Country Programmes
28 February 2018